Simpson P J, Schelm J A, Smith G F
Department of Cardiovascular Research, Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana.
J Pharmacol Exp Ther. 1991 Feb;256(2):780-6.
The purpose of this study was to determine whether normal fibrinogen contributes to the development of myocardial reperfusion injury by acting as a substrate in vivo for neutrophil adhesion. This was tested in a dog model of acute myocardial infarction that used pentobarbital anesthetized dogs subjected to 90 min regional myocardial ischemia and 5 h reperfusion. Dogs were treated with 1 unit/kg Ancrod (venom from the Malayan pit viper, Agkistrodon rhodostoma) or vehicle i.v. 60 min after left circumflex coronary artery occlusion. Therapeutic defibrination was verified in Ancrod-treated dogs by measurements of clottable fibrinogen, alpha-2 antiplasmin and plasminogen, by the activated partial thromboplastin time and by immunoelectrophoresis. Fibrinogen was depleted to below detectable limits of the assay (less than 0.05 mg/ml) after treatment with Ancrod. The defibrination effect was accomplished by the expected activation of the fibrinolytic system: alpha-2 antiplasmin was decreased by 10% and plasminogen activity was decreased by 30% with Ancrod treatment. There were no measureable differences between the two treatment groups in heart rate, mean arterial blood pressure, rate pressure product or circumflex coronary blood flow throughout the 90 min of regional ischemia or during the 5 h of reperfusion. The relative severity of ischemia between the two treatment groups was similar when assessed with radiolabeled microsphere measurement of myocardial blood flow. The accumulation of neutrophils (measured by myeloperoxidase activity) within the myocardium after reperfusion was not reduced by prior depletion of fibrinogen.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是确定正常纤维蛋白原是否通过作为体内中性粒细胞黏附的底物而促进心肌再灌注损伤的发生。这在急性心肌梗死的犬模型中进行了测试,该模型使用戊巴比妥麻醉的犬,使其经历90分钟的局部心肌缺血和5小时的再灌注。在左旋冠状动脉闭塞60分钟后,犬静脉注射1单位/千克安克洛酶(马来亚蝰蛇毒,红口蝮)或赋形剂。通过测量可凝纤维蛋白原、α-2抗纤溶酶和纤溶酶原、活化部分凝血活酶时间以及免疫电泳,验证安克洛酶治疗犬的治疗性去纤维蛋白作用。用安克洛酶治疗后,纤维蛋白原被消耗至检测限以下(低于0.05毫克/毫升)。去纤维蛋白作用是通过预期的纤溶系统激活实现的:安克洛酶治疗使α-2抗纤溶酶降低10%,纤溶酶原活性降低30%。在90分钟的局部缺血期间或5小时的再灌注期间,两个治疗组在心率、平均动脉血压、心率血压乘积或左旋冠状动脉血流量方面没有可测量的差异。用放射性微球测量心肌血流量评估时,两个治疗组之间缺血的相对严重程度相似。再灌注后心肌内中性粒细胞的积聚(通过髓过氧化物酶活性测量)并未因预先消耗纤维蛋白原而减少。(摘要截短于250字)